Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publications 2008

Original Papers

  • Eich HT, Müller R-P, Engenhart-Cabillic R, Lukas P, Schmidberger H, Staar S, Willich N. Involved Node Radiotherapy in early-stage Hodgkin’s Lymphoma – Definition and Guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 2008; 184 (8):406-410.
  • Eich HT, Engenhart-Cabillic R, Hansemann K, Lukas P, Schneeweiß A, Seegenschmiedt MH, Skripnitchenko R, Staar S, Willich N, Müller R-P. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin´s lymphoma – an analysis of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2008; 71(5): 1419-1424.
  • Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Müller R-P, Fuchs M, Borchmann P, Gossmann A, Schicha H, Diehl V, Engert A. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112 (10): 3989-94. [Auswertung HD15 PET]
  • Macann A, Bredenfeld H, Müller R-P, Diehl V, Engert A, Eich HT. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: A report by the German Hodgkin's Lymphoma Study Group. Int J Radiat Oncol Biol Phys. 2008; 70 (1): 161-5.
  • Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A; Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. German Hodgkin Study Group. J Clin Oncol. 2008; 26(3):434-9.
  • Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008; 111(1):109-11. 
  • Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, Fuchs M, Diehl V, Engert A. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol. 2008; 19(10):1795-801.
  • Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, Engert A. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008; 111(1):71-6.


  • Eichenauer DA, Fuchs M, Borchmann P, Engert A; German Hodgkin Study Group. Hodgkin's lymphoma: current treatment strategies and novel approaches. Expert Rev Hematol. 2008; 1(1):63-73.
  • Engert A. Treatment of lymphocyte-predominant Hodgkin lymphoma. Ann Oncol. 2008; 19 Suppl 4:iv45-6. 
  • Engert A, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii65-6.
  • Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008 Sep;5(9):543-56. Review.
  • Fuchs M, Eichenauer DA, Nogová L, Diehl V, Engert A; German Hodgkin Study Group. Nodular lymphocyte-predominant Hodgkin lymphoma. Curr Hematol Malig Rep. 2008 Jul;3(3):126-31. 
  • Fuchs M, Nogová L, Bias HJ, Engert A. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma With Rituximab. The American Journal of Hematology/Oncology 2008; 7(5):180-82.
  1. Fuchs M, Engert A. Integrierte Versorgung; Vom Kompetenznetz Maligne Lymphome e.V. koordiniertes Projekt soll Therapie optimieren. Med Review 2008; 8: 12-13.
  • Klimm B, Engert A. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. Nat Clin Pract Oncol. 2008; 5(6):316-23. 
  • Kobe C, Dietlein M, Mauz-Körholz C, Engert A, Borchmann P, Sabri O, Schober O, Schicha H, Kluge R. FDG-PET in Hodgkin lymphoma. Nuklearmedizin 2008; 47: 235-238.
  • Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A. Yttrium-90 ibritumimab tiuxetan induced complete remission in a patient with classical lymphocyte-rich Hodgkin lymphoma. Onkologie 2008; 31: 49-51.